Over 50% of patients have evidence of MYCN amplification and/or metastatic disease and are therefore considered to have high-risk neuroblastoma (Cheung and Dyer, 2013; Coughlan et al., 2017; Maris et al., 2007; Matthay et al., 2016). This evidence concerns the gene MYCN and neuroblastoma.